Table 2:
Outcomes of the included studies.
| Study name [ref] year, continental area | Non-AKI [n (%)] | ICPi-AKI [n (%)] | Mortality in AKI [n (%)] | Mortality in non-AKI [n (%)] | AKI Stage 1; 2; 3 [n (%)] | Recovered AKI patients’ outcome [n (%)] | Not recovered AKI and outcome (death, need of dialysis, etc.) [n (%)] |
|---|---|---|---|---|---|---|---|
| Cortazar et al. [20] 2020,
North America |
276 (67) | 138 (33) | 67 (48.5) | NA | Stage 2, 59 (43);
Stage 3, 79 (57) |
FR: 54 (40); PR: 63 (45) | NR: 21 (15); death/NR: 15 (71.4) |
| García-Carro et al. [24] 2022,
Europe |
641 (84) | 118 (16) | 82 (69.5) | 315 (49.1) | Stage 1, 69 (58.5);
Stage 2 or 3, 49 (41.5) |
FR: 38 (32) | Death: 82 (20) |
| Gupta et al. [19] 2021,
North America/Europe/Asia |
429 (50) | 429 (50) | 168 (39.2) | NA | Stage 1, 77 (18);
Stage 2, 144 (33.6); Stage 3, 208 (48.5) |
OR: 276 (64.3) | Death: 168 (39.2) |
| Non-AKI [n (%)] | ICPi-AKI [n (%)] | Total mortality | AKI Stage 1; 2; 3 [n (%)] | Recovered AKI patients’ outcome [n (%)] | Not recovered AKI and outcome (death, need of dialysis, etc.) [n (%)] | ||
| Koks et al. [23] 2021,
Europe |
644 (95) | 32 (5) | 314 (46.4) | Stage 1, 26 (81.3);
Stage 2, 6 (18.8); Stage 3, 0 (0) |
OR: 19 (59.4) | NR: 13 (40.6) | |
| Meraz-Muñoz et al. [21] 2020,
North America |
297 (96) | 12 (4) | Total mortality: 222 (72%) | (NOT only ICPi induced);
Stage 1, 27 (53); Stage 2, 11 (22); Stage 3, 13 (25) |
FR: 5 (41.6); PR: 5 (41.6) | NR: 2 (16.7) | |
| Seethapathy et al. [22] 2020,
North America |
594 (99) | 5 (1) | 1 (20) | NA | Stage 1, 1 (20);
Stage 2, 3 (60); Stage 3, 1 (20) |
FR: 2 (40); PR: 1 (20) | NR: 2 (40);
death/NR: 1 (50) |
| Shimamura et al. [18] 2021,
Asia |
125 (82) | 27 (18) | 17 (63) | 68 (54) | Stage 1, 17 (63);
Stage 2, 8 (30); Stage 3, 2 (7) |
FR: 19 (73) | NR: 8 (27) |
NA, not applicable; ICPi-AKI, immune checkpoint inhibitor–induced acute kidney injury; FR, fully recovered; PR, partially recovered; OR, overall recovery of patients in the study; NR, non recovered